Skip to main content

Advertisement

SpringerLink
Log in

Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

While no PD-1 inhibitor has been FDA approved for use in sarcoma or proven efficacious in a randomized trial, the use of single agent PD-1 inhibitors is standard-of-care and recommended by the NCCN guidelines in certain specific subtypes and situations. Even while the role of immunotherapy is still being defined in sarcoma, there is rising interest in combinations of PD-1 inhibitors with standard-of-care treatments, especially chemotherapy. Recently, several early phase trials have suggested potential benefits for chemotherapy in combination with PD-1 inhibitors. Although some physicians are already combining PD-1 inhibitors and chemotherapy for sarcoma off-label in the community, we believe more data is necessary. We support further evaluation of these combinations in well-designed clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Katz D, Palmerini E, Pollack SM. More than 50 subtypes of soft tissue sarcoma: paving the path for histology-driven treatments. Am Soc Clin Oncol Educ Book. 2018;38:925–38. https://doi.org/10.1200/EDBK_205423.

    Article  Google Scholar 

  2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. https://doi.org/10.1016/S0140-6736(13)60106-3.

    Article  CAS  Google Scholar 

  3. Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020;27(Suppl 1):17–23. https://doi.org/10.3747/co.27.5407.

    Article  CAS  Google Scholar 

  4. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovee J, et al. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934–42. https://doi.org/10.1002/cncr.33618.

    Article  Google Scholar 

  5. Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200–29. https://doi.org/10.3322/caac.21605.

    Article  Google Scholar 

  6. Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.

    Article  Google Scholar 

  7. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. The Lancet Oncology. 2017;18(11):1493–501. https://doi.org/10.1016/S1470-2045(17)30624-1.

    Article  CAS  Google Scholar 

  8. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The Lancet Oncology. 2017;18(10):1397–410. https://doi.org/10.1016/S1470-2045(17)30622-8.

    Article  CAS  Google Scholar 

  9. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23. https://doi.org/10.1016/S1470-2045(14)70063-4.

    Article  CAS  Google Scholar 

  10. Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol. 2019;20(1):6.

    Article  Google Scholar 

  11. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. The Lancet Oncology. 2018;19(3):416–26. https://doi.org/10.1016/S1470-2045(18)30006-8.

    Article  Google Scholar 

  12. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870. https://doi.org/10.1371/journal.pone.0082870.

    Article  CAS  Google Scholar 

  13. Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, et al. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015;6(14). https://doi.org/10.18632/oncotarget.3498.

  14. Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123:3291–304. https://doi.org/10.1002/cncr.30726.

  15. Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, et al. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021;9(8). https://doi.org/10.1136/jitc-2021-002812.

  16. Goff PH, Riolobos L, LaFleur BJ, Spraker MB, Seo YD, Smythe KS, et al. Neoadjuvant therapy induces a potent immune response to sarcoma, dominated by myeloid and B cells. Clin Cancer Res. 2022. https://doi.org/10.1158/1078-0432.CCR-21-4239.

  17. Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM. Systemic interferon-gamma increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. Cancer Immunol Res. 2019;7(8):1237–43. https://doi.org/10.1158/2326-6066.CIR-18-0940.

    Article  CAS  Google Scholar 

  18. Pollack SM, Ingham M, Spraker MB, Schwartz GK. Emerging targeted and immune-based therapies in sarcoma. Journal of Clinical Oncology. 2018;36(2):125–35. https://doi.org/10.1200/JCO.2017.75.1610.

    Article  CAS  Google Scholar 

  19. Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, et al. Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol. 2022;40(12):1291–300. https://doi.org/10.1200/JCO.20.03452.

    Article  CAS  Google Scholar 

  20. Ben-Ami E, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Severgnini M, Patel T, Cunningham A, Rodig SJ, Hodi FS, Morgan JA, Merriam P, Wagner AJ, Shapiro GI, George S. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123(17):3285–90. https://doi.org/10.1002/cncr.30738.

    Article  CAS  Google Scholar 

  21. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. The Lancet Oncology. 2022;23:1156–66. https://doi.org/10.1016/S1470-2045(22)00392-8.

  22. Nathenson M, Choy E, Carr ND, Hibbard HD, Mazzola E, Catalano PJ, et al. Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): report of LMS cohort. J Clin Oncol. 2020;38(15_suppl):11559. https://doi.org/10.1200/JCO.2020.38.15_suppl.11559.

    Article  Google Scholar 

  23. Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020. https://doi.org/10.1038/s41586-019-1906-8.

  24. Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28(6):1199–206. This reference is of importance because it underscores the presence of intratumoral tertiary lymphoid structures as a potential predictive biomarker to improve patient selection for pembrolizumab and pembrolizumab combination therapies. https://doi.org/10.1038/s41591-022-01821-3.

    Article  CAS  Google Scholar 

  25. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay J-Y, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos A, van der Graaf W, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. The Lancet Oncology. 2014;15(4):415–23. https://doi.org/10.1016/S1470-2045(14)70063-4.

    Article  CAS  Google Scholar 

  26. Ryan CW, Merimsky O, Agulnik M, Blay J-Y, Schuetze SM, Tine BAV, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016;34(32):3898–905. https://doi.org/10.1200/JCO.2016.67.6684.

    Article  CAS  Google Scholar 

  27. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. The Lancet Oncol. 2017;18(8):1089–103. https://doi.org/10.1016/S1470-2045(17)30381-9.

    Article  CAS  Google Scholar 

  28. Tap WD, Wagner AJ, Schoffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266–76. https://doi.org/10.1001/jama.2020.1707.

    Article  CAS  Google Scholar 

  29. Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017;117(1):33–40. https://doi.org/10.1038/bjc.2017.145.

    Article  CAS  Google Scholar 

  30. Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial. JAMA Oncol, 82. 2020;6(11):1778 This reference is of importance because it highlights that the combination of doxorubicin with pembrolizumab is promising and worthy of further study, especially in UPS and dedifferentiated LPS.

  31. Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, Foureau DM, Maxwell DM, Baldrige EA, Begic X, Symanowski JT, Steuerwald NM, Anderson CJ, Patt JC, Kneisl JS, Kim ES. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft-tissue sarcoma. Clin Cancer Res. 2021;27(23):6424–31. https://doi.org/10.1158/1078-0432.CCR-21-2001.

    Article  CAS  Google Scholar 

  32. Rosenbaum E, Qin L-X, Thornton KA, Movva S, Nacev BA, Dickson MA, et al. A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS). J Clin Oncol. 2022;40(16_suppl):11516. https://doi.org/10.1200/JCO.2022.40.16_suppl.11516.

    Article  Google Scholar 

  33. Padron LJ, Maurer DM, O’Hara MH, O’Reilly EM, Wolff RA, Wainberg ZA, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167–77. https://doi.org/10.1038/s41591-022-01829-9.

    Article  CAS  Google Scholar 

  34. Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, et al. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021;10(11):3565–74. https://doi.org/10.1002/cam4.3903.

    Article  CAS  Google Scholar 

  35. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786–93. https://doi.org/10.1200/JCO.2015.62.4734.

    Article  CAS  Google Scholar 

  36. Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Tanase T, Hasegawa T, Takahashi S. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. The Lancet Oncology. 2015;16(4):406–16. https://doi.org/10.1016/S1470-2045(15)70098-7.

    Article  CAS  Google Scholar 

  37. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249–62. https://doi.org/10.1016/j.ccr.2013.01.008.

  38. Schroeder BA, Zhang Y, Smythe KS, Desai P, Thomas A, Viveiros P, et al. Immunologic gene signature analysis correlates myeloid cells and M2 macrophages with time to trabectedin failure in sarcoma patients. Cancers (Basel). 2022;14(5). https://doi.org/10.3390/cancers14051290.

  39. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Research. 2010;70(6):2235–44. https://doi.org/10.1158/0008-5472.CAN-09-2335.

  40. Belgiovine C, Frapolli R, Liguori M, Digifico E, Colombo FS, Meroni M, Allavena P, D'Incalci M. Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy. Eur J Immunol. 2021;51(11):2677–86. https://doi.org/10.1002/eji.202149379.

    Article  CAS  Google Scholar 

  41. Chawla SP, Sankhala KK, Ravicz J, Kang G, Liu S, Stumpf N, et al. Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. J Clin Oncol. 2018;36(15_suppl):e23568-e.

    Article  Google Scholar 

  42. Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, et al. A phase 1/2 trial combining avelumab and trabectedin for advanced liposarcoma and leiomyosarcoma. Clin Cancer Res. 2022;28(11):2306–12. This reference is of importance because it highlights a clear association between higher T-cell receptor clonality and partial response by RECIST criteria, identifying a potential mechanism for improving future study enrollment stratification. https://doi.org/10.1158/1078-0432.CCR-22-0240.

  43. Toulmonde M, Brahmi M, Giraud A, Chakiba C, Bessede A, Kind M, Toulza E, Pulido M, Albert S, Guégan JP, Cousin S, Mathoulin-Pelissier S, Perret R, Croce S, Blay JY, Ray-Coquard I, Floquet A, Italiano A. Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study. Clinical Cancer Research. 2022;28(9):1765–72. https://doi.org/10.1158/1078-0432.CCR-21-2258.

    Article  CAS  Google Scholar 

  44. Gordon EM, Chua VS, Kim TT, Chawla NS, Brigham DA, Bhuiyan I, et al. A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma. J Clin Oncol. 2021;39(15_suppl):11562. https://doi.org/10.1200/JCO.2021.39.15_suppl.11562.

    Article  Google Scholar 

  45. Demetri GD, Schoffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 2017;35(30):3433–9. https://doi.org/10.1200/JCO.2016.71.6605.

    Article  CAS  Google Scholar 

  46. Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011;47(4):515–9. https://doi.org/10.1016/j.ejca.2010.11.025.

    Article  CAS  Google Scholar 

  47. Heylmann D, Bauer M, Becker H, van Gool S, Bacher N, Steinbrink K, Kaina B. Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLOS ONE. 2013;8(12):e83384. https://doi.org/10.1371/journal.pone.0083384.

    Article  CAS  Google Scholar 

  48. Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):93–7. https://doi.org/10.1001/jamaoncol.2017.1617.

    Article  Google Scholar 

  49. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. The Lancet Oncol. 2019;20(6):837–48. https://doi.org/10.1016/S1470-2045(19)30153-6.

    Article  CAS  Google Scholar 

  50. Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020;8(2). https://doi.org/10.1136/jitc-2020-001561.

  51. Dickson MA, Schwartz GK, Keohan ML, D’Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, Tap WD. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol. 2016;2(7):937–40. https://doi.org/10.1001/jamaoncol.2016.0264.

    Article  Google Scholar 

  52. Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy. 2022;7(1):258.

    Article  Google Scholar 

  53. Cho BC, Shin SJ, Lee J-L, Shim BY, Park HS, Yun N, et al. 470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59). J ImmunoTher Cancer. 2021;9(Suppl 2):A499-A.

    Article  Google Scholar 

  54. University of C. Study of PD1 blockade by pembrolizumab with stereotactic body radiotherapy in advanced solid tumors. 2020. https://doi.org/10.12688/wellcomeopenres.15824.2.

  55. Institut B, Roche Pharma AG, National Cancer Institute F, Seven, Eight Biopharmaceuticals I. Atezolizumab combined with BDB001 and immunogenic radiotherapy in patients with advanced solid tumors. 2023.

  56. D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944–57. https://doi.org/10.1158/2159-8290.CD-17-1417.

    Article  CAS  Google Scholar 

  57. National Cancer I, National Institutes of Health Clinical C. NK white blood cells and interleukin in children and young adults with advanced solid tumors. 2015.

  58. Baylor College of M, Center for C, Gene Therapy BCoM, The Methodist Hospital Research I, Cancer Prevention Research Institute of T. Her2 chimeric antigen receptor expressing T cells in advanced sarcoma. 2019.

  59. St. Jude Children’s Research H. B7-H3-specific chimeric antigen receptor autologous T-cell therapy for pediatric patients with solid tumors (3CAR). 2026.

  60. National Cancer I. Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in children, adolescents, and young adults with relapsed/refractory osteosarcoma and neuroblastoma, The GD2-CAR PERSIST Trial. 2024.

  61. Sun Yat-sen U, Guangdong Xiangxue Precision Medical Technology Co L. NY-ESO-1-specific T cell receptor (TCR) T cell in sarcoma. 2023.

  62. Center UNCLCC. Study of CAR T-cells targeting the GD2 with IL-15+iCaspase9 for relapsed/refractory neuroblastoma or relapsed/refractory osteosarcoma. 2024.

  63. Baylor College of M, Center for C, Gene Therapy BCoM, The Methodist Hospital Research I, Cancer Prevention Research Institute of T. C7R-GD2.CART cells for patients with relapsed or refractory neuroblastoma and other GD2 positive cancers (GAIL-N). 2023.

  64. National Cancer I. Talimogene laherparepvec and radiation therapy in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. 2022. https://doi.org/10.5249/jivr.v15i1.1655.

  65. Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, et al. A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab. Clin Cancer Res. 2019;25(7):2096–108. https://doi.org/10.1158/1078-0432.CCR-18-3496.

  66. Birdi HK, Jirovec A, Cortes-Kaplan S, Werier J, Nessim C, Diallo JS, et al. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J Immunother Cancer. 2021;9(2). https://doi.org/10.1136/jitc-2020-001580.

  67. Petitprez F, de Reyniès A, Keung EZ, Chen TWW, Sun CM, Jeng YM, Hsiao LP, Lacroix L, Lucchesi C, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Lazar AJ, Roland CL, Wargo J, Italiano A, Sautès-Fridman C, Tawbi HA, Fridman WH. Immune classification of soft tissue sarcoma predicts clinical outcome. Annals of Oncology. 2019;30:v689. https://doi.org/10.1093/annonc/mdz283.011.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Meghan M. Lynch PharmD

  2. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Borislav A. Alexiev MD

  3. Department of Hematology and Medical Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Brett A. Schroeder MD

  4. Department of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, 303 E. Superior St. #3-115, Chicago, IL, 60611, USA

    Seth M. Pollack MD

Authors
  1. Meghan M. Lynch PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Borislav A. Alexiev MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brett A. Schroeder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seth M. Pollack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seth M. Pollack MD.

Ethics declarations

Conflict of Interest

Meghan M. Lynch: The author has no relevant financial or non-financial interests to disclose.

Borislav A. Alexiev: The author has no relevant financial or non-financial interests to disclose.

Brett A. Schroeder: The author has no relevant financial or non-financial interests to disclose.

Sethan M. Pollack: Advisory board, received honorarium or consulting fees from GlaxoSmithKline, Springworks, Apexigen, Blueprint Medicine, Daiichi Sankyo, T-knife, Deciphera, Aadi Biosciences, Epizyme, Obsidian, and Bayer.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lynch, M.M., Alexiev, B.A., Schroeder, B.A. et al. Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma. Curr. Treat. Options in Oncol. 23, 1861–1876 (2022). https://doi.org/10.1007/s11864-022-01036-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-022-01036-1

Keywords

Search

Navigation